Mirum Pharmaceuticals

MIRM · NASDAQ

$85.07+$2.83 (+3.44%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $82.24

Latest news

Press releaseOct 15, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsOct 12, 9:38 AM ETVandana Singh
Why Is Mirum Pharmaceuticals Stock Gaining Monday?
Press releaseOct 12, 8:00 AM ETBusiness Wire
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Press releaseOct 11, 5:00 PM ETBusiness Wire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
NewsSep 28, 8:38 AM ETVandana Singh
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
Press releaseSep 28, 8:00 AM ETBusiness Wire
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Press releaseSep 27, 5:00 PM ETBusiness Wire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Press releaseSep 25, 7:00 PM ETBusiness Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
NewsSep 25, 2:53 PM ET
FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily
Press releaseSep 14, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseSep 8, 8:30 AM ETBusiness Wire
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Press releaseAug 11, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsAug 5, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 5, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 29, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Press releaseJul 13, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 14, 4:35 PM ETBusiness Wire
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
Press releaseJun 11, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJun 4, 8:05 AM ETBusiness Wire
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Press releaseMay 30, 12:00 PM ETBusiness Wire
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Press releaseMay 21, 8:05 AM ETBusiness Wire
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Press releaseMay 14, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 12, 11:56 PM ETBusiness Wire
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Press releaseMay 12, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Press releaseMay 12, 8:00 AM ETBusiness Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
NewsMay 6, 5:03 PM ET
Earnings Scheduled For May 6, 2026
Press releaseMay 6, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
NewsMay 4, 11:15 AM ETVandana Singh
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
Press releaseMay 4, 8:00 AM ETBusiness Wire
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Press releaseMay 3, 5:00 PM ETBusiness Wire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026
Press releaseApr 29, 4:01 PM ETBusiness Wire
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
NewsFeb 26, 1:01 PM ET
13 Analysts Have This To Say About Mirum Pharmaceuticals
NewsFeb 25, 6:11 AM ET
Earnings Scheduled For February 25, 2026
NewsFeb 24, 12:01 PM ET
Insights Ahead: Mirum Pharmaceuticals's Quarterly Earnings
NewsJan 26, 8:00 AM ET
Expert Outlook: Mirum Pharmaceuticals Through The Eyes Of 11 Analysts
NewsDec 19, 12:07 PM ETAvi Kapoor
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday
NewsNov 5, 6:45 AM ET
What Analysts Are Saying About Mirum Pharmaceuticals Stock
NewsNov 4, 4:02 PM ET
Mirum Pharmaceuticals Q3 EPS $0.05 Beats $(0.14) Estimate, Sales $133.010M Beat $130.074M Estimate

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Is Mirum Pharmaceuticals Stock Gaining Monday?

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Health Care Stocks Moving In Wednesday's After-Market Session

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Earnings Scheduled For May 6, 2026

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026

Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

13 Analysts Have This To Say About Mirum Pharmaceuticals

Earnings Scheduled For February 25, 2026

Insights Ahead: Mirum Pharmaceuticals's Quarterly Earnings

Expert Outlook: Mirum Pharmaceuticals Through The Eyes Of 11 Analysts

Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday

What Analysts Are Saying About Mirum Pharmaceuticals Stock

Mirum Pharmaceuticals Q3 EPS $0.05 Beats $(0.14) Estimate, Sales $133.010M Beat $130.074M Estimate